Homocysteine: a new cardiac risk factor?

Area of Science:

• Cardiovascular Medicine
• Biochemistry

Background:

• Elevated plasma homocysteine is a newly identified risk factor for coronary artery disease (CAD).
• Hyperhomocysteinemia may contribute to vascular damage through various mechanisms.
• Understanding homocysteine metabolism is crucial for cardiovascular health.

Purpose of the Study:

• To review the role of homocysteine in coronary artery disease.
• To examine secondary causes of elevated homocysteine.
• To evaluate the efficacy of B vitamin supplementation for hyperhomocysteinemia.

Main Methods:

• Literature review of studies on homocysteine metabolism and CAD.
• Analysis of clinical evidence linking hyperhomocysteinemia to cardiovascular risk.
• Review of data on B vitamin supplementation effects on homocysteine levels.

Main Results:

• Hyperhomocysteinemia is implicated as a significant risk factor for CAD.
• B vitamin supplementation, particularly folate, can lower homocysteine concentrations.
• Current evidence suggests a potential benefit of folate supplementation in high-risk individuals.

Conclusions:

• Folate supplementation (400 mcg) is recommended for patients with established CAD or high cardiovascular risk.
• This approach is considered safe and effective in the absence of definitive clinical trial data.
• Further prospective trials are needed to confirm the long-term benefits.